UNSPSC 51191572: Amiloride hydrochloride

This classification denotes a potassium-sparing diuretic and intercalating agent with the molecular formula C6H8ClN7O.ClH.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FZJ37245UC, chemically known as pyrazinecarboxamide, n-amidino-3,5-diamino-6-chloro-, monohydrochloride but more generally known as amiloride hydrochloride, which bears US NIH Compound Identifier 16230. European Medicines Agency schedules Amiloride hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00445MIG.

UNSPSC 51191572 Amiloride hydrochloride is a Commodity code covering pharmaceutical products, though recent state and local procurement activity under this code shows minimal targeted solicitations for the specific drug; instead, state and local buyers typically source amiloride and related pharmaceuticals through broader generic-drug cooperative purchasing agreements rather than as standalone line items. When pharmaceutical procurement does occur under related codes, state and local governments buy diuretics and other specialty medications primarily through established supply chains managed by authorized wholesalers, with pricing evaluated on a unit-cost or WAC-minus basis and compliance with FDA cGMP and Drug Supply Chain Security Act (DSCSA) requirements mandatory.

The issuing bodies for multi-source pharmaceutical procurement span state departments, cooperative purchasing alliances, and individual municipalities. Geographic activity appears concentrated in states with active cooperative purchasing vehicles, particularly Minnesota through MMCAP (Minnesota Multistate Cooperative Purchasing Alliance), which administers agreements effective across multiple states including Oregon. A representative recent opportunity is the Minnesota Department of Administration's MMCAP RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026, with proposals due March 26, 2026, establishing contracts effective July 1, 2026, through authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC. Evaluation weights pricing competitiveness at 75 percent, with manufacturers required to certify cGMP compliance, maintain relationships with at least two authorized wholesalers, and carry commercial general liability of $5,000,000 per occurrence and network security and privacy liability of $2,000,000. No specific dollar ceiling or set-aside designation was disclosed.